Page last updated: 2024-09-03

mr 2034 and beta-funaltrexamine

mr 2034 has been researched along with beta-funaltrexamine in 1 studies

Compound Research Comparison

Studies
(mr 2034)
Trials
(mr 2034)
Recent Studies (post-2010)
(mr 2034)
Studies
(beta-funaltrexamine)
Trials
(beta-funaltrexamine)
Recent Studies (post-2010) (beta-funaltrexamine)
4800542154

Protein Interaction Comparison

ProteinTaxonomymr 2034 (IC50)beta-funaltrexamine (IC50)
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)0.082
Prostaglandin G/H synthase 1Homo sapiens (human)0.082
Delta-type opioid receptorMus musculus (house mouse)0.082
Kappa-type opioid receptorMus musculus (house mouse)0.082
Mu-type opioid receptorMus musculus (house mouse)0.082

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Smith, CB1

Other Studies

1 other study(ies) available for mr 2034 and beta-funaltrexamine

ArticleYear
New approaches to the evaluation of opioid agonists and antagonists upon the isolated, electrically stimulated mouse vas deferens preparation.
    NIDA research monograph, 1987, Volume: 76

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Benzodiazepines; Benzomorphans; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Enkephalins; Male; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Oligopeptides; Pyrrolidines; Receptors, Opioid; Vas Deferens

1987